Parallax Volatility Advisers’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Parallax Volatility Advisers’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-81,800	Closed	-$7.44M	–	3001
2023 Q1	$7.44M	Buy	+81,800	New	+$4.8M	0.02%	683
2021 Q2	–	Sell	-20,000	Closed	-$2M	–	1815
2021 Q1	$2M	Hold	20,000	–	–	﹤0.01%	698
2020 Q4	$2.47M	Buy	+20,000	New	+$2.63M	﹤0.01%	1192
2020 Q3	–	Sell	-1,900	Closed	-$299K	–	3217
2020 Q2	$299K	Buy	1,900 +900	+90%	+$137K	﹤0.01%	2144
2020 Q1	$142K	Buy	+1,000	New	+$193K	﹤0.01%	2065

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parallax Volatility Advisers's RETA Position: Q2 2023 in Review

Parallax Volatility Advisers sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2023, closing a stake of 48 shares — an estimated $4.36K sold.

Parallax Volatility Advisers first reported a position in RETA in Q4 2017 and held it in 9 quarters. The position peaked at $339K in Q1 2019. 214 funds tracked by Wall St. Rank hold RETA as of Q2 2023.

Parallax Volatility Advisers reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
Parallax Volatility Advisers sold 48 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2023, an estimated $4.36K.
Parallax Volatility Advisers first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2017 and held it in 9 quarters.
Parallax Volatility Advisers's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $339K in Q1 2019.
214 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2023.

Based on Parallax Volatility Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.